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We explore relationships linking clinical symptoms, respiratory dysfunction, and local production of proinflammatory chemokines in the
pneumonia virus of mice (PVM) model of viral bronchiolitis. With a reduced inoculum of this natural rodent pathogen, we observe virus clearance
by day 9, while clinical symptoms and respiratory dysfunction persist through days 14 and 17 postinoculation, respectively. Via microarray and
ELISA, we identify expression profiles of proinflammatory mediators MIP-1α, MCP-1, and MIP-2 that correlate with persistent respiratory
dysfunction. MIP-1α is localized in bronchial epithelium, which is also the major site of PVM replication. Interferon-γ was detected in lung tissue,
but at levels that do not correlate with respiratory dysfunction. Taken together, we present a modification of our pneumovirus infection model that
results in improved survival and data that stand in support of a connection between local production of specific mediators and persistent
respiratory dysfunction in the setting of acute viral bronchiolitis.
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Viral bronchiolitis is a common infection of infants and
young children that is associated with significant morbidity. The
most common etiologic agents are viruses of the family
Paramyxovirdae, including human respiratory syncytial virusAbbreviations: PVM, pneumonia virus of mice; MIP-1α, macrophage
inflammatory peptide-1α; MIP-2, macrophage inflammatory protein-2; MCP-
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CCR1, CC chemokine receptor 1; IL-8, interleukin-8; PIV, parainfluenza
virus; MPV, metapneumovirus; SIV, simian immunodeficiency virus; WBP,
whole body unrestrained plethysmography; KC, keratinocyte-derived chemo-
kine; Th-1, T helper type-1; TNF-α, tumor necrosis factor alpha; CCL2, CC
chemokine ligand 2.
⁎ Corresponding author.
E-mail address: domachoj@upstate.edu (J.B. Domachowske).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
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(hMPV; also subfamily Pneumovirinae), and parainfluenza
viruses (PIVs; subfamily Paramyxovirinae). Clinical studies
performed on samples from human infants suggest that
expression of virus-induced chemoattractant cytokines such as
macrophage inflammatory protein-1α (MIP-1α; CCL3), mono-
cyte chemotactic protein type 1 (MCP-1; CCL2), RANTES
(regulated on activation, normal T-cell expressed and secreted;
CCL5), and interleukin-8 (IL-8; CXCL-8) correlates with the
severity of illness (Harrison et al., 1999; Smyth et al., 2002;
Welliver et al., 2002). These findings have been replicated to
some extent by studies in animal models of respiratory virus
infection. In the mouse model of hRSV challenge, elevated
concentrations of MIP-1α, RANTES, and MCP-1 were detected
in lung tissue following virus challenge (Haeberle et al., 2001;
Jafri et al., 2004; Miller et al., 2004). Similarly, in the cotton rat
model, levels of growth-regulated protein (GROα; CXCL1),
MIP-1β (CCL4), RANTES, IL-1β, IL-6, interferons α and γ,
Fig. 1. (A) Clinical symptom scores and virus titers on days 0–28
postinoculation. Clinical symptom scores (left ordinate, solid line) for mice
inoculated on day 0 with 30 pfu PVM (n = 62). Scoring system based on six
points, with one point given for each of the following: hunched posture, ruffled
fur, abnormal gait, labored breathing, lethargy, and emaciation. Data are
expressed as mean clinical symptom score + SEM. Clinical scores are
statistically different from baseline on days 5–12 (*P < 0.01). Mean virus
titer + SEM [pfu/gm × 106 from Table 1] is shown by the dotted line and right
ordinate. Inset: % original weight on days 5, 7, and 10 postinoculation (n = 3
mice per point; *P < 0.02). (B and C) Microscopic histology of mouse lung
tissue at day 7 postinoculation with 30 pfu PVM. Arrows indicate the
granulocytic inflammation predominant about the large bronchioles.
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increased following hRSV challenge (Blanco et al., 2002).
One of the limitations of the aforementioned rodent models
is that they cannot replicate the more severe forms of the human
disease (reviewed in Domachowske et al., 2004; Rosenberg et
al., 2005). When these human pneumovirus pathogens are used
to challenge rodents, virus inocula in the range of 1 to 10 million
plaque-forming units (pfu) are required to achieve limited
infection with few associated respiratory symptoms (Collins et
al., 2001). To overcome the limitations of hRSV in rodent
challenge models, we have developed a mouse model of viral
bronchiolitis using the rodent-specific pathogen, pneumonia
virus of mice (PVM; family Paramyxoviridae, genus Pneumo-
virus). To date, our published work has focused on defining and
characterizing disease pathogenesis using a primarily lethal
inoculum of the PVM strain J3666. Pathogenesis studies
performed using relatively high titers (>60 pfu) of this virus
have demonstrated that the chemokine MIP-1α is an essential
mediator of virus-induced cellular inflammation (Doma-
chowske et al., 2000). When the innate inflammatory response
is diminished via genetic, immunologic, or pharmacologic
means, we observe reduced morbidity and mortality if the
antiviral drug ribavirin is administered concurrently (Bonville et
al., 2003, 2004). In this study, we have altered our approach,
and have identified an inoculum at which ∼75% of the PVM-
infected mice ultimately survive. With this reduced inoculum,
we can explore objective measures of lung dysfunction in
correlation with clinical symptoms and local production of
proinflammatory mediators both during and following severe
respiratory virus infection. We compare these results to those
obtained in earlier studies using standard inocula of the hRSV
pathogen in mice.
Results
Survival in response to increasing inocula of PVM strain J3666
Mice (40 per group) were inoculated with 5, 10, 30, or 60 pfu
PVM in a 50 μl volume. Survival was 100%, 95%, 75%, and
10%, respectively, at t = 28 days postinoculation. All
subsequent experiments were performed with an inoculum of
30 pfu.
Clinical symptom scores
Clinical symptoms, including hunched posture, ruffled fur,
abnormal gait, labored breathing, lethargy, and emaciation,
and weight loss (% original weight) were determined in
response to a 30 pfu inoculum as shown in Fig. 1A. Clinical
symptom scores reached a peak on day 6 (n = 62 mice), and,
among the 46 surviving mice (74%), clinical scores did not
return to the baseline (zero) until day 17, a full 8 days after
virus could no longer be detected by plaque assay. Sham-
infected mice remain asymptomatic throughout (data not
shown). Histologic examination of lung tissue from mice on
day 7 postinoculation provided evidence of acute bronchiolitis
(Figs. 1B and C).Gene microarray analysis and confirmation of protein
expression
Gene microarray analysis performed on lung RNA from
PVM-infected mice inoculated with 30 pfu and harvested on
days 1, 3–7, 10, 14, 21, and 28 postinoculation; each sample
was compared individually to lung RNA from uninfected mice
treated otherwise identically. Of 39,000 potential transcripts
included on the M430_2 microarray chip, we identified 44
(r = 0.90) with temporal expression patterns following that of
the respiratory and clinical dysfunction. We focused specifically
on transcripts that exhibited >5-fold elevation over baseline at
days 6 and 7, with evidence of gradually diminishing expression
thereafter (Fig. 2). The expression profile for the proinflamma-
tory chemokine, MIP-1α, is highlighted in white. In the inset,
the profiles of the proinflammatory chemokines MCP-1 and
MIP-2, and the antiviral cytokine, interferon-γ are included.
Both MIP-1α and MCP-1 have been implicated as proin-
flammatory mediators in the pathogenesis of human RSV
infection (Noah and Becker, 2000) as has IL-8, the human
ortholog of mouse MIP-2 (Harrison et al., 1999; Smyth et al.,
2002; Zhang et al., 2001; Oh et al., 2002). Durbin et al. (2002)
and van Schaik et al. (2000) have presented evidence indicating
that IFN-γ functions to promote a protective Th1 response
during primary RSV infection. Transcripts encoding the Th2
Fig. 2. Tracking specific gene microarray expression patterns in response to PVM infection. The uninfected baseline (day 0) is set as default (1.0) and the levels of
expression on days 1, 3–7, 10, 14, 21, and 28 are compared using algorithms from GeneSpring. Shown are the 44 transcripts from the total 39,000 from the Affymetrix
M430_2 microarray chip that follow the respiratory dysfunction profile shown, with peak expression at days 6 and 7, diminishing gradually thereafter. The white
overdrawn line documents the expression profile of the proinflammatory chemokine, MIP-1α. Inset: expression profiles of MIP-1α, MCP-1, MIP-2, and interferon-γ.
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did not respond to PVM infection; slight elevations (<2-fold) in
transcripts encoding TNF-α were detected at days 6 and 7
postinoculation, but no immunoreactive protein was detected.
Detection of immunoreactive MIP-1α, MIP-2, MCP-1, and
IFN-γ in lung homogenates by ELISA is documented in Tables
1 and 2. Chemokine and cytokine responses to PVM are
presented together with those taken from the literature
documenting analogous responses to primary challenge of
mice with hRSV, as these two pneumovirus challenge models
are often compared to one another (Jafri et al., 2004; Miller et
al., 2004). There are prominent differences in the patterns of
chemokine and cytokine responses in the PVM and hRSV
models. Chemokine responses to intranasal inoculation of
30 pfu PVM (MIP-1α, MCP-1, MIP-2) are detected in a
consistent, monophasic pattern, with peak values at days 6 and
7, corresponding with peak virus titer. The pattern differs
markedly in response to hRSV challenge, either administered
intransally (107 pfu) (Jafri et al., 2004) or intratracheally, via
surgical incision (5 × 104 pfu) (Miller et al., 2004). In nearly
every case, the response observed to hRSV challenge was
biphasic response, often with the larger of the two peaks
occurring at day 0 or 1 postinoculation. Interestingly, this is not
the case for interferon-γ, where the patterns in response to PVM
and hRSV are roughly equivalent, with monophasic peak
responses at day 7 and day 5 (Jafri et al., 2004), respectively.
Immunohistochemical localization of MIP-1α
We have shown previously that MIP-1α signaling via its
major receptor, CCR1, is a crucial mediator of the inflammatory
response to PVM infection. The expression profile of the
transcript encoding MIP-1α is prototypical of the relevantproinflammatory mediators, as it peaks at day 7, and gradually
diminishes, returning to baseline at day 14, although immuno-
reactive MIP-1α can be detected in lung homogenates at levels
that are statistically above baseline as late as day 21
postinoculation (Table 1). Immunohistochemical localization
indicates that MIP-1α is produced in the bronchiolar epitheli-
um, which is also the cellular localization of PVM replication
(Fig. 3).
Whole body unrestrained plethysmography (WBP) of
PVM-infected mice
WBP was performed on PVM-infected but otherwise
unchallenged mice; representative waveforms measured at
baseline (day 0) and on days 5, 6, 7, 10, 11, and 14
postinoculation are shown in Fig. 4. Among the most striking
observations was the presence of apneic pauses (arrowheads)
observed on days 6 and 7 at the peak of clinical symptoms
(see Fig. 1). Plethysmographic changes from the baseline,
including prolonged expiratory component of the waveform,
were first observed on day 5 and continued through day 17
postinoculation.
Analysis of the mean expiratory times captured for the 62
PVM-infected mice evaluated is shown in Fig. 5A. Mean
expiratory times significantly longer than the baseline
(0.068 ± 0.012) were first observed on day 5 (0.11 ± 0.01 s).
This difference reached a maximum on day 7 (0.14 ± 0.03 s)
before gradually returning to the baseline (0.08 ± 0.01 s) on day
21 (for all values, P < 0.01 vs. baseline). Mean Penh (Fig. 5B)
first increases to 1.47 ± 0.6 over the baseline of 0.65 ± 0.2 on
day 5, reaching a maximum on day 6 (2.7 ± 0.7) and remaining
elevated through day 11 (1.2 ± 0.4, all values P < 0.05 vs.
baseline).
Table 1
Chemokines detected in whole lung homogenates from PVM-infected and hRSV-challenged mice
MIP-1α MCP-1 MIP-2 KC
Array
fold
change
ELISA
pg/ml/mg
PVM
ELISAa
pg/ml hRSV
ELISAb
pg/ml/mg
hRSV
Array
fold
change
ELISA pg/ml/mg
PVM
ELISAb
pg/ml/mg
hRSV
Array
fold
change
ELISA
pg/ml/mg/
PVM
ELISAa
pg/ml/mg/
hRSV
ELISAb
pg/ml/mg/
hRSV
0 – ND 260 ± 60c – – 35 ± 18 – – ND 6800 ±
700c
–
1 1 ND 100c 25 ± 5c 1 48 ± 14 180 ± 50c 1 ND 3000 85 ± 15c
2 ND ND – 7 ND 73 ± 21 30 ND ND – 25
3 1 ND b b 1 66 ± 10⁎ b 1 ND 500 b
4 1.7 ND 80c b 1 752 ± 130⁎ b 1 ND 400 b
5 11 71 ± 14⁎ 150 ± 40c 15 ± 5 9.1 1860 ± 318⁎ 40 ± 10 3.5 62 ± 8⁎ b 15
6 29 448 ± 90⁎ – 15 ± 3c 26 3040 ± 490⁎ 40 ± 5 7.8 188 ± 37⁎ – 15
7 38 698 ± 152⁎ 50⁎ – 15 2220 ± 270⁎ – 6.2 146 ± 12⁎ b –
8 – – 40⁎ 30 ± 10c – – 100 ± 30c – – b 35c
10 11 261 ± 43⁎ b – 5.8 1260 ± 280⁎ – 1.3 49 ± 9⁎ b –
14 2.4 34 ± 12⁎ b – 1 331 ± 78⁎ – 1 6 ± 3⁎ b –
21 1 35 ± 30⁎ – – 1 132 ± 45⁎ – 1 ND – –
28 1 6 ± 3⁎ – – 1 12 ± 8 – 1 ND – –
Data generated from gene microarray (PVM) are presented as fold-differences from day zero (n = 5 mice per time point). Data generated by ELISA (PVM) are
presented as mean immunoreactive protein concentration ± SEM (n = 3 mice per time point). Data in boldface are peak time points in the series. ND, none detected.
b, values reported at baseline in aforementioned publications. –, time points not evaluated.
a hRSV data adapted from Fig. 4 of Jafri et al. (2004), reprinted with permission.
b hRSV data adapted from Fig. 4 of Miller et al. (2004), reprinted with permission.
c Data reported as statistically significant over baseline in the aforementioned publications.
⁎ P < 0.01 compared to uninfected baseline.
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symptom score recorded for the individual mice at single time
points (n = 62 mice). We observed a direct correlation between
measured Penh and clinical symptom score in otherwise
unchallenged, PVM-infected mice (Fig. 6).Table 2
Proinflammatory cytokine interferon-gamma detected in whole lung homogenates
from PVM-infected and hRSV-challenged mice
IFN-γ
Array-fold change ELISA pg/ml/mg PVM ELISAa pg/ml hRSV
0 – ND b
1 1 ND b
2 1 ND b
3 1 ND b
4 1 90 ± 14⁎ 6000 ± 1200b
5 8.3 210 ± 68⁎ 13,000 ± 700b
6 16 434 ± 96⁎ –
7 13 1070 ± 222⁎ 2000 ± 300b
8 – – b
10 2.6 189 ± 84⁎ b
14 1 85 ± 12⁎ b
21 1 ND –
28 1 ND –
Data generated from gene microarray (PVM) are presented as fold-differences
from day zero (n = 5 mice per time point). Data generated by ELISA (PVM) are
presented as mean immunoreactive protein concentration ± SEM (n = 3 mice per
time point). hRSV data are from figures from literature references as noted. Data
in boldface are peak time points in the series. ND, none detected.
b, values reported at baseline in aforementioned publications. –, time points not
evaluated.
a hRSV data from Fig. 4 of Jafri et al., reference 5 (hRSV).
b Data reported as statistically significant over baseline in the aforementioned
publications.
⁎ P < 0.01 compared to uninfected baseline.Respiratory dysfunction correlates with levels of
proinflammatory mediators in the lung
To determine whether local concentrations of the identified
proinflammatory mediators correlate with the measured
changes in pulmonary function, WBP was performed on
infected mice on days 0 to 14 just prior to sacrifice; lung
tissue was retrieved and processed for cytokine and
chemokine analysis. Scattergrams were generated by plottingFig. 3. Immunohistochemical detection of MIP-α and PVM virus antigens. (A
and B) Detection of PVM in bronchiolar epithelial cells on day 6 postinoculation
with 30 pfu PVM with mouse anti-PVM antisera and biotinylated protein G,
original magnifications 40× and 63×, respectively. (C and D) Detection of MIP-
1α in bronchiolar epithelial cells on day 6 postinocuation with 30 pfu PVMwith
(C) irrelevant goat antibody or (D) goat anti-mouse MIP-1α followed by
biotinylated rabbit anti-goat Ig. Original magnification, 40×.
Fig. 4. Whole body plethysmography tracings. Fifteen second whole body
plethysmography (WBP) tracings at baseline (day 0) and on days 5–7, 10, 11,
and 14 following inoculation with 30 pfu PVM. Arrowheads identify apneic
pauses in the respiratory waveforms.
Fig. 6. Enhanced pause (Penh) vs. clinical symptom scores on days 0–14, 21,
and 28 postinoculation. Penh correlates with clinical symptom scores, r2 = 0.74.
Mean values of Penh at a given clinical score are shown as horizontal bars.
91C.A. Bonville et al. / Virology 349 (2006) 87–95the concentration of each mediator against the Penh (Fig. 7).
Strong correlations between Penh and MIP-1α (r2 = 0.64),
MCP-1 (r2 = 0.63) and MIP-2 (r2 = 0.74) were determinedig. 5. (A) Expiratory times (Te) and (B) enhanced pause (Penh) on days 0–28
ostinoculation. Mice were inoculated on day 0 with 30 pfu PVM, and
spiratory waveforms were captured for 5 min at each time point for each
ouse (n = 62). Data are expressed as mean expiratory time + SEM. Values are
atistically different from baseline on days shown (*P < 0.01).F
p
re
m
stwhen these parameters where measured in individual mice
(n = 48). Interestingly, despite similarities in the overall
trend in expression pattern, there was only limited correla-
tion between Penh and IFN-γ (r2 = 0.28) among individual
mice.
Discussion
In previous studies, we have focused on the more severe
sequelae of PVM strain J3666 infection in wild type strains of
mice and on immunotherapeutic interventions (Domachowske
et al., 2000; Bonville et al., 2003, 2004). Here we demonstrate
that simply by reducing the number of virions in the inoculum
to 30 pfu in 50 μl, we can reduce the severity of the illness,
most notably by reducing mortality from 90% to 25% in the
C57BL/6 strain of mice. This minor modification presents a
model that is more closely in line with parameters observed in
human clinical settings, providing further evidence for the
usefulness of this virus in the in vivo modeling of human
RSV.
We have examined otherwise unchallenged, PVM-infected
mice using whole body unrestrained plethysmography (WBP)
as an objective measure of airway dysfunction. Our intent in
employing WBP measurements was to augment our more
observational clinical criteria with direct, objective measures of
respiratory dysfunction and to generate a data set that could be
compared directly to WBP measurements generated for the
hRSV challenge model (Jafri et al., 2004; van Schaik et al.,
2000; Schwarze et al., 1999a, 1999b; Ikemura et al., 2000;
Schwarze and Schauer, 2004; Chavez-Bueno et al., 2005;
Mejias et al., 2004). Interestingly, specific WBP results from
PVM infected mice differ markedly from those obtained in
response to hRSV challenge. To the best of our knowledge,
there are no reports of apneic pauses in any study of hRSV
challenge in mice. Furthermore, in a recent study of hRSV
challenge model (Jafri et al., 2004), peak virus titer was reported
on day 4, while elevations in Penh over background levels were
observed on days 5–9 postinoculation. In contrast, in the PVM
infection model, peak virus titer is observed on day 7 and
elevated Penh, on days 6–11 postinoculation. Thus, elevations
in Penh in the PVM model correlate with the peak of virus titer,
Fig. 7. Enhanced pause (Penh) vs. lung chemokine concentration. (A) MIP-1α, (B) MCP-1, (C) MIP-2, and (D) IFN-γ. Whole body plethysmography was performed
on each mouse immediately prior to sacrifice on days 0 to 14 (n = 48).
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after virus titer had declined.
The observation that expiratory time and Penh are both
prolonged during acute PVM infection is indicative of severe
lower respiratory tract inflammation and supports our hypoth-
esis that pneumovirus-induced bronchiolitis causes obstructive
lung disease. The somewhat unexpected finding that these
perturbations in the expiratory phase of the waveform persisted
even when virus was no longer detected suggests that the
inflammatory responses to the infection are, at least in part,
driving the obstructive (and perhaps bronchoconstrictive)
process. A second major whole body plethysmographic finding
was the presence of prolonged apneic pauses, i.e., breaks in the
normal respiratory cycle, during the peak of the infection (Fig.
4, arrowheads). The cause of apnea in this context has not yet
been explored, but the clinical correlate in infants with hRSV
infection is well known. Speculation regarding the mechanism
of apnea in hRSV-infected infants includes local and central
neurogenic causes. Recently, Tripp et al. (2003) presented data
showing that the hRSV attachment G protein can cause apnea
via a specific induction of substance P.
In the PVM model, all measures of disease activity – clinical
symptom scores, respiratory function, and proinflammatory
chemokine concentrations – remain elevated from baselinevalues for a full 8 days after active virus replication can no
longer be detected by plaque assay. This observation is
consistent with earlier findings, suggesting a pivotal role for
persistent inflammatory responses in prolonging and exacer-
bating the severity of the disease process in both PVM infection
in mice and in human disease.
In this work, we have identified three proinflammatory
chemokines that correlate specifically with respiratory dysfunc-
tion and clinical symptomatology, and those serve as an
additional link between the pathologies of hRSV and pneumo-
nia virus of mice in their respective hosts. The most prominent
of the chemokines detected on gene microarray in response to
PVM infection are MIP-1α, MIP-2 (an ortholog of human IL-
8), and MCP-1 (see Fig. 2 and Table 1). In our earlier patient
study, in which we evaluated lung wash fluid from intubated
infants, we found that the chemokines MIP-1α and IL-
8 predominated in those infants intubated secondary to RSV,
but not those intubated secondary to other causes, even
secondary to other respiratory virus infections (Harrison et al.,
1999). Likewise, Welliver et al. (2002) observed that nasal wash
concentrations of MIP-1α and MCP-1 are significantly higher
in infants with hypoxic vs. nonhypoxic RSV-bronchiolitis, and
Garofalo et al. (2001) documented the correlation of MIP-1α
with hRSV-associated disease severity.
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PVM infection can be compared and contrasted to those
performed with another natural rodent respiratory virus model,
Sendai virus, also known as Parainfluenza virus type I. Sendai is a
virus of the family Paramyxovirdae, genus Paramyxovirus.
Doherty and colleagues (Mo et al., 1995a; Hou and Doherty,
1995; Hou et al., 1994; Hyland et al., 1994; Mo et al., 1995b;
Topham andDoherty, 1998) were among the first to evaluate host
responses to Sendai, and defined specific CD4+ andCD8+ Tcell,
and their respective cytokine responses observed at ∼7–10 days
postinoculation in C57BL/6 mice. Indeed, these studies were
among those that defined the concept of CD8+ memory T cells
(Hou et al., 1994). Likewise, Lemanske, Castleman, Sorkness,
and colleagues (Sorkness et al., 1991, 2002a, 2002b; 2002c;
Mehta et al., 1997; Stokes et al., 1998; Cai and Castleman, 2002;
Rosenthal et al., 2004; Cai and Castleman, 2003; Stone et al.,
2003) have explored the functional responses of two defined
strains of rats – the Brown Norway (BN) and Fischer 344
(F344) – to infection with the Sendai virus pathogen. Weanlings
of the former strain of rats respond to Sendai infection with an
asthmatic-type, postbronchiolitis response, while the latter
display a resistant phenotype. Among the findings, the
production of interferon-gamma by the F344 rats and its absence
in the BN rats are associated with the airway hyperreactivity; that
increases in IL-13 and/or IL-12, but not persistence of viral RNA
appear to be related to pathology; that early expression of IP-10
could contribute to resistance; and that treatment with imiquimod
(an agent that induces production of interferon-α) likewise
reduces the symptomatology among the BN rats. Interestingly,
although interferon-gamma is produced in C57BL/6 mice in
response to PVM infection, we observed no specific correlation
between levels of interferon-gamma and the degree of respiratory
dysfunctionmeasured in individual mice (see Fig. 7). However, it
remains possible that the presence of this cytokine alone at some
threshold level serves a protective function, as van Schaik et al.
(2000) and Durbin et al. (2002) have documented the importance
of this cytokine in limiting hRSV replication and hRSV-induced
inflammatory responses in BALB/c mice. Experimental evalu-
ation of gene-expression and respiratory dysfunction in PVM-
infected interferon-gamma and/or interferon-gamma receptor
gene-deleted mice might yield intriguing results.
PVM infection in the mouse host replicates many of the more
severe features that typify the pathogenesis of human
pneumovirus disease. PVM is without question a rodent-
specific pathogen, just as hRSV is a human (or primate)-specific
pathogen, and bRSV is a bovine-specific pathogen. Each
pathogen has adapted to its specific host, replicates effectively,
engages an evolutionarily relevant innate immune system, and
as such, causes respiratory disease in its specific host with many
shared features. This is not unexpected, as each pathogen is of
the same Family (Paramyxoviridae) and subfamily (Pneumo-
virinae) and genus (Pneumovirus). PVM infection in mice
replicates clinical features of hRSV infection in humans—
inflammatory bronchiolitis associated with the production of
specific proinflammatory chemokines and robust virus replica-
tion in situ. We have used the PVMmodel to explain the limited
clinical utility of glucocorticoids, the poor clinical resultsobserved in response to monotherapy with ribavirin, and we
have recently used the PVMmodel to explore the use of specific
immunomodulatory agents (Domachowske et al., 2001, 2004;
Rosenberg et al., 2005; Bonville et al., 2003, 2004). At the
reduced inoculum featured in this manuscript, we have come
even closer to replicating the features of the more typical case of
moderate to severe hRSV as experienced by a human infant.
In summary, our observations indicate that inflammation and
respiratory dysfunction persist beyond the period of maximum
virus replication. The existence of persistent inflammation and
ongoing respiratory dysfunction support a role for specific anti-
inflammatory and/or immunomodulatory treatment of pneumo-
virus infection for reasons that go beyond simply survival.
Further studies on the natural history of disease resolution, lung
remodeling, and the impact of different therapeutics using
pneumonia virus of mice as described here are now possible.
Materials and methods
Mouse and virus stocks
Six- to eight-week-old C57BL/6 mice were obtained from
Taconic Laboratories (Germantown, NY and Rockville, MD).
PVM J3666 stocks for inoculations were maintained by mouse-
passage only. Preparation of virus stocks and determination of
titers by standard plaque assay on BS-C-1 cells (American Type
Culture Collection, Manassas, VA) were as previously de-
scribed (Domachowske et al., 2000). All mice were documented
as free of mouse hepatitis virus, parvovirus, and pinworms. All
animal work was reviewed and approved as per animal study
protocols CHUA #634 (SUNY Syracuse) or ASP #LAD-8E
(NIAID).
Establishing and documenting symptoms related to viral
infection
Under light isofluorane anesthesia, all mice were inoculated
intranasally with 5, 10, 30, or 60 pfu PVM J3666 (as determined
by standard plaque assay) in 50 μl phosphate-buffered saline
(PBS). Clinical symptoms were recorded daily for mice
inoculated with 30 pfu; whole body unrestrained plethysmog-
raphy (WBP; see below) was performed for a 5 min period on
all mice on days indicated. The clinical scoring of infected mice
is a modification of the system originally described by Cook et
al. (1998). For the purposes of this study, we have converted the
original scoring to a six point system in which one point is given
for each of the following symptoms: hunched posture, ruffled
fur, abnormal gait, labored breathing, lethargy, and emaciation.
Pulmonary function measurements
WBP was assessed daily during the first 2 weeks postinoc-
ulation and weekly thereafter through 28 days postinoculation.
Unanesthetized mice were placed in a whole body plethysmo-
graph (model PLY 3211; Buxco Electronics, Inc., Troy, NY).
Respiratory parameters were obtained for a minimum of 5 min
using chamber pressure as measured by a transducer that is
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software. Pulmonary airflow obstruction was measured by the
dimensionless parameter ‘enhanced pause’ (Penh) where
Penh = [(Te / RT) − 1] × (PEF/PIF), where Penh = enhanced
pause (dimensionless), Te = expiratory time(s), RT = relaxation
time(s), PEF = peak expiratory flow (ml/s), and PIF = peak
inspiratory flow (ml/s).
Gene microarray analysis
Lungs were removed from PVM-infected mice (n = 5 per time
point) and immediately immersed in 7 ml of RNazol reagent and
processed as previously described (Domachowske et al., 2002).
The quantity of RNA obtained was determined spectrophotomet-
rically at 260 and 260/280 nm, and sample integrity was confirmed
by formaldehyde-agarose gel electrophoresis. All microarray
procedures were carried out using the M430_2 mouse microarray
chip at the Microarray Core Facility in Rochester, NY, also as
previously described (Domachowske et al., 2002). Comparisons of
gene expression patterns among the different experimental
conditions were determined using algorithms included in the
GeneSpring 6.2 software package (Silicon Genetics).
Chemokine and cytokine determinations
Concentrations of MIP-1α, MCP-1, MIP-2, interferon-γ,
and interleukins 4, 5, and 13 were determined on total lung
homogenates using commercially available ELISA kits (R&D
Systems, Minneapolis, MN). For specific experiments, WBP
parameters were captured immediately prior to sacrifice so that
functional parameters and cytokine concentrations could be
determined for individual mice (n = 48).
Immunohistochemical detection of PVM and MIP-1α
Paraffin blocks of formalin-fixed infected lung tissue were
cut and stained using previously described techniques (Haines
and Chelack, 1991) using 1% albumin as blocking reagent,
1:150 dilution of mouse anti-PVM (strain 15) convalescent
antiserum, and 1:100 dilution of biotinylated protein G and
developing reagents to detect PVM replication in lung tissue. To
detect MIP-1α, a 1:50 dilution of goat anti-MIP-1α primary
antibody (R&D Systems, Minneapolis, MN) was used,
followed by a 1:400 dilution of biotinylated rabbit anti-goat
Ig and developing reagents. Routine H&E staining of formalin-
fixed tissue was performed by American Histolabs (Gaithers-
burg, MD).
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